Importantly, IFNβ, a therapeutic used in some MS patients, works to limit CNS inflammation through this mechanism, as the anti-inflammatory effect of IFNβ is lost in AHR-deficient astrocytes (55). Here, IFNB1 is linked to myeloid sarcoma.